New rail pass expands coverage across eastern Japan, making it easier for international travelers to explore Tohoku’s seasonal landscapes, festivals, and cultural destinations.

TOKYO, March 17, 2026 /PRNewswire/ — East Japan Railway Company (JR East) has announced the launch of a newly expanded JR EAST PASS, available from March 14, 2026. Tohoku, comprising six prefectures in northern Honshu, is emerging as one of Japan’s most compelling year-round destinations for travelers venturing beyond the major metropolitan hubs. However, it currently accounts for just 1.5 percent of overnight stays by inbound visitors. Recognizing the significant potential for further growth, JR East aims to increase that share to 5 percent by 2034 by improving rail accessibility and encouraging deeper regional exploration.

New JR EAST PASS:  https://www.jreast.co.jp/en/multi/pass/eastpass.html

The new JR EAST PASS replaces both the former JR EAST PASS (Tohoku area) and JR EAST PASS (Nagano, Niigata area) with a single consolidated pass that offers unlimited access to reserved seats in ordinary cars across all JR East lines, including Shinkansen, limited express, express, local, and rapid services. Coverage also includes select partner railways, such as Tokyo Monorail, and regional operators, ensuring smooth airport access and regional connectivity.

The pass is available in two formats:

• 5 consecutive days – ¥35,000 (Child: ¥17,500)
• 10 consecutive days – ¥50,000 (Child: ¥25,000)

*Note: Adult (12 years and older) / Child (6 to 11 years old)

Unlocking Tohoku

The JR EAST PASS unlocks multi-region travel, making Tohoku’s year-round attractions more accessible than ever for inbound travelers. In spring, travelers can venture northwards, utilizing the 10-day pass to chase the cherry blossom season in April at spectacular sites such as Miharu Takizakura in Fukushima and Hirosaki Park in Aomori. Alternatively, they can escape the heat and humidity of summer in Tokyo to explore Tohoku’s cooler coastlines and mountain villages. Summer also brings celebration across the region, with famous festivals, from the Aomori Nebuta Festival’s huge illuminated floats to the vibrant streamers of the Sendai Tanabata Festival in Miyagi. In the fall, foliage paints the mountain landscapes a kaleidoscope of color, while winter transforms locations such as Yamagata’s Zao Onsen and Iwate’s Appi Kogen into ‘Japow’ powder-snow paradises.

The unified JR EAST PASS offers a flexible, cost-effective solution for travelers planning multi-city itineraries across eastern Japan. Destinations such as Nagano, known for its alpine landscapes and winter sports, and Niigata, celebrated for its coastal scenery and sake breweries, are firm favorites with international visitors. The pass also includes Tokyo and the surrounding prefectures of Gunma, Kanagawa, and Chiba, as well as parts of Shizuoka, offering access to hot spring towns, mountain retreats, and coastal destinations within easy reach of the capital.

*More high-res images of Tohoku throughout the year are available for download here. Please refer to the file names for image credit information.

Images for Press: https://bit.ly/JRE-Tohoku-Media

With the newly broadened coverage, travelers can now continue north into Tohoku, reaching cities such as Aomori, Akita, and Sendai, without purchasing multiple regional tickets. Journeys between Tokyo and these destinations can entail substantial transport costs when purchased individually, and reserving seats further enhances convenience during peak travel seasons.

The expansion reflects JR East’s broader strategy to encourage travelers to move beyond established hubs and support more balanced regional tourism growth across eastern Japan.

[Ayumi Utagawa], Project Manager of East Japan Railway Company, said:

“As global interest in Japan continues to rise, we want to support more balanced tourism growth and sustainable regional revitalization. The JR EAST PASS removes barriers to deeper exploration, allowing travelers to experience the full richness of regional Japan, from its metropolises to its rural communities, onsen towns, and expansive landscapes. This region offers remarkable natural beauty and cultural richness across all four seasons, yet it remains underrepresented in many itineraries. We sincerely hope you will discover the Japan that is still unknown to many through the “JR EAST PASS.”

Additional Benefits

JR EAST PASS holders can also take advantage of JRE Rewards, offering hundreds of discounts and special offers at stations, restaurants, and local shops across eastern Japan when travelers present their pass.

JRE Rewards: https://www.jreast.co.jp/en/multi/jreastrewards/

Simplified Purchasing

The pass can be purchased through the JR-EAST Train Reservation online platform, JR EAST Travel Service Centers, major stations within the coverage area, and participating overseas travel agencies. The expanded JR EAST PASS is available to all non-Japanese passport holders, regardless of visa status, including foreign residents living in Japan.

In addition, several other rail products were updated on March 14, 2026:

• JR East–South Hokkaido Rail Pass (6 days, ¥40,000) – Expanded to include Niigata.
• Hokuriku Arch Pass (7 days, ¥35,000) – Expanded to include the Tokyo metropolitan area, Chuo Line, and Oito Line.
• JR TOKYO Wide Pass (3 days, ¥16,000) – Revised pricing.
• N’EX TOKYO Round Trip Ticket (¥5,200) – Revised pricing.
• JR Tohoku–South Hokkaido Rail Pass (6 days, ¥32,000) – Revised pricing.
• SENDAI AREA PASS (1 day, ¥1,420) – Revised pricing.

For detailed information on the JR EAST PASS and all other passes mentioned, please visit [Find Your Pass]  https://www.jreast.co.jp/en/multi/pass/

About East Japan Railway Company (JR East):
East Japan Railway Company (JR East) is one of the world’s leading rail operators, managing an extensive network of approximately 7,500 kilometers and serving more than 16 million passengers each day across eastern Japan. Expanding beyond traditional rail operations, JR East is committed to supporting regional revitalization and enhancing the travel experience across Japan. Through its “Beyond the Border” strategy, the company integrates transportation with retail, hospitality, and digital services, including innovations such as the “Suica Renaissance.” In July 2025, JR East unveiled its Group Management Vision, “To the Next Stage” 2034 (Yusho 2034). From a human-centric, market-in perspective, the company aims to create new value through “Lifestyle Transformation (LX),” delivering peace of mind and inspiration to all stakeholders.

Company Name:                           East Japan Railway Company
Location:                                       2-2-2 Yoyogi, Shibuya-ku, Tokyo, Japan
Establishment:                              April 1, 1987
Paid-In Capital:                             200,000 million JPY
Total Number of Shares Issued:   1,134,412,200
Listed stock exchange:                 Tokyo Stock Exchange Prime Market
Representative:                             Yoichi KISE, President and CEO
Corporate Website:                      https://www.jreast.co.jp/en/company/

Press Release (PDF): https://bit.ly/JRE-Tohoku-Media-20260317-PressRelease
Media Contact:
Overseas PR Representatives, Bluemoon Marketing Inc.
E-mail: jreast@bluemoonmarketing.jp
* Media inquiries only 

Source

Developer-favorite desktop robot now available to more consumers worldwide through AliExpress Anniversary Sale

LOS ANGELES, March 17, 2026 /PRNewswire/ — Reachy Mini, the open-source desktop robot that has captivated the developer community, is now available to global consumers on AliExpress, coinciding with the platform’s Anniversary Sale promotion. This extension marks an important step in expanding Reachy Mini beyond the open-source developer community to a broader consumer audience across key markets including the United States, Europe, South Korea, Japan and Brazil.

Developed within the Hugging Face ecosystem, a leading open-source AI platform, Reachy Mini is a flagship embodied AI project designed for human-AI interaction, creative coding, and hands-on experimentation. Reachy Mini has earned strong recognition among AI researchers and developers worldwide. Now, through AliExpress, the robot is becoming more broadly accessible to consumers interested in exploring the next wave of AI-powered robotics.

The addition of Reachy Mini reflects AliExpress’ broader push to attract innovative technology products and brands. Seeed Studio, the hardware manufacturing partner behind Reachy Mini, selected AliExpress as its consumer market launchpad.

“AliExpress has made a strong commitment to supporting premium hard tech products, which aligns perfectly with Seeed Studio’s mission,” said Joey Jiang, VP of Global Sales and Marketing at Seeed Studio. “As an open-source hardware provider focused on emerging technologies, we have built a technology ecosystem based on open-source hardware, AI-driven capabilities, and cross-domain co-creation. The Anniversary Sale gives us a rare opportunity to tap into global demand and introduce Reachy Mini to a wider audience.”

The timing comes amid growing visibility for Reachy Mini. At CES 2026, NVIDIA CEO Jensen Huang featured Reachy Mini in his keynote address, demonstrating the desktop robot to a global audience and signaling that the era of embodied AI has arrived. The spotlight from one of the world’s most-watched tech stages has helped drive surging interest and pre-order demand for the compact robot.

From March 16 through March 25, Reachy Mini will be available in stock – no pre-orders required. Seeed Studio’s official AliExpress store will release limited units daily throughout the promotional period, giving consumers worldwide a chance to own one of the most talked-about robots in the embodied AI space.

Reachy Mini is among a growing roster of premium tech brands joining AliExpress Brand+, the platform’s dedicated channel for high-end global technology brands. In 2025, Unitree Robotics opened its official flagship store on AliExpress, while Rokid AR glasses and other emerging global tech brands have used the platform to reach international consumers directly. As more frontier technology brands seek global scale, AliExpress is emerging as the platform of choice for hard tech brands looking to grow beyond their home markets.

“Reachy Mini joining AliExpress during our Anniversary Sale is a strong signal of where consumer technology is headed,” said Chris Carl, Head of Marketing, AliExpress U.S. “We aim to bring the world’s most innovative technology products to consumers everywhere.”

Reachy Mini is available HERE through Seeed Studio’s official AliExpress store.

About AliExpress

Launched in 2010, AliExpress is a global e-commerce platform dedicated to creating a better shopping experience for hundreds of millions of consumers in more than 200 countries and regions. In addition to the English version, the AliExpress platform is available in 15 other languages. AliExpress is part of Alibaba International Digital Commerce Group.

Source

NYSE issues a pre-market daily advisory direct from the trading floor.

NEW YORK, March 16, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Ashley Mastronardi delivers the pre-market update on March 16^th

• Markets are fractionally higher as investors monitor the latest oil price movement.
• Ireland INC President Ian Hyland joins NYSE Live after ringing the Opening Bell to recognize the strong economic ties between the U.S. and Ireland.
• Frore Systems reached unicorn status after securing a $143 million Series D funding round.
• CoinDesk will launch a weekly show that explores the intersection of traditional finance and digital assets. 

For market insights, IPO activity, and today’s opening bell, download the NYSE TV app at tv.nyse.com

Opening Bell
Ireland Day and Ireland INC celebrate amplification of the significant Irish investment across the United States

Closing Bell
She Means Business and Citizens (NYSE: CFG) celebrate International Women’s Day and the Citizens “She Means Business” Program

Click here to download the NYSE TV App

EltaMD rang the Closing Bell on March 13.

Source

HONG KONG, March 16, 2026 /PRNewswire/ — Located in the heart of Tsim Sha Tsui, Honeymoon Dessert, one of Hong Kong’s most well-loved dessert chains, has strengthened its commitment to innovation with the introduction of Aigens Mobile Ordering on WeChat. The new digital ordering solution was launched ahead of the 2026 Chinese New Year Golden Week to efficiently manage the anticipated surge of customers from Mainland China—and it continues to deliver lasting benefits to both tourists and locals throughout the year.

With WeChat Mobile Ordering, dine-in customers can browse Honeymoon Dessert’s entire menu simply by scanning the WeChat QR code placed on their table. Orders can be placed directly within a WeChat Mini Program, and payment is completed seamlessly through WeChat Pay, without any redirection to external pages. This fully integrated experience is especially convenient for Mainland visitors, who are already familiar with WeChat’s all-in-one ecosystem.

The new system delivers major advantages for both guests and staff. Customers enjoy a frictionless dining journey—ordering at their own pace, reviewing menu images and descriptions, and adding items easily at any time during their meal. Meanwhile, Honeymoon Dessert benefits from greater operational efficiency, reduced waiting times, and optimized table turnover, all while providing a modern, user-friendly dining experience that enhances customer satisfaction.

Mr. Ken Mui, Human Resources and Administration Manager of Honeymoon Dessert, shared his appreciation for the partnership: “Aigens WeChat Ordering has transformed the way we serve our guests. It’s fast, intuitive, and exactly what our customers expect in today’s digital dining environment.”

Even beyond the festive period, the solution continues to support the strong tourism demand driven by the 37.8 million visitors from Mainland China who came to Hong Kong in 2025, many of whom frequent the Tsim Sha Tsui area year-round. By offering a familiar and convenient ordering experience, Honeymoon Dessert ensures it remains a preferred destination for visitors seeking authentic Hong Kong-style desserts.

Aigens Mobile Ordering on WeChat is available to F&B outlets of all sizes and concepts across Hong Kong. Restaurant operators interested in adopting the system can reach out to Aigens for a free consultation and discover how digital ordering can enhance their operations.

About Aigens Technology Limited:

Aigens Technology Limited, founded in 2012, is a leading provider of digital restaurant solutions, trusted by the world’s most reputable QSR, restaurant groups, food courts, hotels & resorts, airports, and casinos, across Hong Kong SAR, Singapore, Australia, and Southeast Asia. Renowned for delivering cutting-edge restaurant QR ordering, kiosk ordering, loyalty, payment, and system integration solutions, Aigens powers over 7,000 locations with seamless, robust, and scalable technologies.

Source

MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®^[1], Floretyrosine F 18 or ¹⁸F-FET), an investigational PET^[2] imaging agent for the characterization of recurrent or progressive glioma (brain cancer) from treatment related changes in both adult and pediatric patients.

Telix has resubmitted the NDA with the additional data requested by the FDA. The Company believes, based on the Type A meeting and ongoing consultation with the FDA, that the additional data and statistical analysis, along with the primary data set provided in the original submission, appropriately addresses the Complete Response Letter^[3].

Given the potential to address significant unmet medical need, TLX101-Px has been granted Orphan Drug^[4] and Fast Track^[5] designations by the FDA. PET imaging with ¹⁸F-FET is already included in international clinical practice guidelines for the imaging of gliomas^[6], however there is currently no FDA-approved targeted amino acid PET agent for adult and pediatric brain cancer imaging commercially available in the U.S.

Dr. David N. Cade, Telix Group Chief Medical Officer, said, “We appreciate the FDA’s recognition of the critical unmet need to improve the diagnosis and management of glioma, particularly in the post-treatment setting. Our resubmission is supported by an extensive and compelling data set – particularly so for an orphan indication. We are grateful to our global clinical collaborators, who share our commitment to ensuring patients in the U.S. can benefit from this important patient management tool.”

Maggie Haynes, Executive Director, Head for the Cure Foundation, added: “Our community is encouraged by the FDA’s ongoing engagement and guidance to the sponsor and support for the Expanded Access Program for TLX101-Px. We are hopeful of an expedited review, so this important and proven imaging option can become available to those who urgently need it.”

About TLX101-Px

TLX101-Px is a PET imaging agent, which has been granted fast track and orphan drug designations by the FDA as an imaging agent for the characterization of recurrent or progressive glioma from treatment related changes. TLX101-Px targets membrane transport proteins known as LAT1 and LAT2^[7]. This enables TLX101-Px to be potentially utilized as a companion diagnostic agent to TLX101-Tx (iodofalan ¹³¹I), Telix’s LAT1-targeting glioblastoma (GBM) therapy candidate, currently under investigation in the pivotal IPAX-BrIGHT study^[8]. 

About gliomas in the U.S.

Gliomas are very diffusely infiltrative tumors that affect the surrounding brain tissue. They are the most common form of central nervous system (CNS) neoplasm that originates from glial cells, accounting for approximately 30% of all brain and CNS tumors and 80% of all malignant brain tumors^[9]. In the U.S., there are six cases of gliomas diagnosed per 100,000 people every year^[10]. GBM is a high-grade glioma and the most common and aggressive form of primary brain cancer, with approximately 22,000 new cases diagnosed annually in the U.S.^[11]. The mainstay of treatment for GBM comprises surgical resection, followed by combined radiotherapy and chemotherapy. Despite such treatment, recurrence occurs in almost all patients^[12], with an expected survival duration of 12-15 months from diagnosis^[13]. 

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies, with the goal to address significant unmet medical needs in oncology and rare diseases. With international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan, Telix is headquartered in Melbourne, Australia. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) has been approved by the U.S. FDA^[14]. TLX101-Px and TLX101-Tx have not received marketing authorizations in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

Source